Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the effect of an alternative dosing strategy of
ruxolitinib in subjects with primary myelofibrosis (PMF), post-polycythemia
vera-myelofibrosis (PPV-MF) and post essential thrombocythemia-myelofibrosis (PET-MF) in
order to minimize the development of anemia and thrombocytopenia.